A leading podiatrist and business owner who has completed nearly 1000 treatments using our revolutionary Swift® device has hailed its potential as the future of treating painful skin lesions.
Joseph Egan, Dublin-based podiatrist had bought a Swift® device for his clinic in 2023 and instantly started seeing positive results in his three clinics across Ireland.
Joseph, who is the owner and director of MyFeet, explained that he was convinced to implement the device into his clinic after seeing promising research on its results - and has since reaped the benefits of our highly effective treatment.
Joseph said: “We are seeing hugely positive results for patients across our clinics. I’ve been really impressed with how effective treatment with the device has been.
“When you compare this against more traditional forms of treatment such as cryotherapy or treating with salicylic acid, the difference is night and day.
“For us, it’s been a positive step change, leading to a much easier process. Using Swift means we don’t have to provide protective padding or dressings and they don’t need regularly changed.
“Additionally, patients aren’t having to go through persistent pain every week that they otherwise would if they went down other routes like cryotherapy, acid or invasive surgery.”
Unlike other traditional treatments, Swift utilises revolutionary microwave technology, targeting the tissue with a highly controlled dose of energy, with research showing that the treatment has an efficacy rate of up to 86.4% on verrucae.
Over 345,000 treatments have been performed across the world and our innovative microwave technology is undergoing trials as a treatment for conditions such as fungal nail, facial acne and melanoma.
Speaking about the future of treatments, Joseph added: “In my opinion Swift is currently the most effective form of treatment clinicians can provide for their patients when it comes to warts and verrucae.
“The research is what convinced us to start using it and it’s been an excellent decision from both a patient care and business standpoint and we’ve not looked back since.
“From a business perspective, we recouped what we paid for the device in three to four months, which is a massive bonus. From the get-go, we’ve wanted to improve our treatments for customers and Swift® has managed to do that – almost instantly.”
Emblation was founded in 2008 by Gary Beale and Eamon McErlean, who met during post-graduate studies at Heriot Watt university.
Speaking on Joseph’s feedback, Chief Commercial Officer, Jonathan Williams said: “It’s obviously incredibly encouraging and motivating to hear such positive feedback about Swift.
“The treatment has proved to be a real game changer when it comes to patients’ quality of life, and we’re still very early into our journey in Ireland. We’re happy Swift® has had such an impact for Joseph and most importantly his patients and we can’t wait to continue to grow Swift’s presence across the country.”
In May 2021, the Emblation secured major second round investment from London based specialist healthcare investors, Apposite Capital with their eight-figure injection of capital already seeing headcount growth of more than 50%, with staff numbers expecting to double again in the next 18 months.
This financial injection also paved the way for the establishment of new Emblation subsidiaries in Canada and Germany, in addition to their expansion into more than 20 other countries.
To find out more about MyFeet visit: myfeet.ie
UK & Ireland 
Deutschland 
United States 